Research programme: gene therapy - Pfizer

Drug Profile

Research programme: gene therapy - Pfizer

Alternative Names: BMB-001; BMB-D001; PF 06939926

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bamboo Therapeutics
  • Developer Pfizer
  • Class Gene therapies
  • Mechanism of Action Dystrophin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 12 Dec 2017 Pfizer plans a phase Ib trial for Duchenne muscular dystrophy (In children) in USA in December 2017 (NCT03362502)
  • 01 Aug 2016 Bamboo Therapeutics has been acquired by Pfizer
  • 10 Jan 2016 Preclinical trials in Duchenne muscular dystrophy in USA (Parenteral) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top